Rimonabant (SR141716): Selective CB1 Antagonist for Appetite Research

Executive Summary: Rimonabant (SR141716) exhibits high affinity for the cannabinoid CB1 receptor (Ki = 1.8 nM) and shows over 285-fold selectivity versus CB2 (Ki = 514 nM), establishing its role as a precise tool for endocannabinoid system modulation (APExBIO product information). It is DMSO soluble at ≥23.19 mg/mL and ethanol soluble at ≥57.1 mg/mL, but insoluble in water. In preclinical research, rimonabant reliably precipitates withdrawal and modulates food intake in rodent models (Sex Differences in Cannabinoid Withdrawal). APExBIO supplies rimonabant as SKU B1429, supporting robust workflows in appetite, obesity, and inflammation research. Protocols consistently reference its benchmarked performance for CB1-specific blockade in vitro and in vivo.

Biological Rationale

The endocannabinoid system critically regulates appetite, energy balance, and neurobehavioral responses. CB1 receptors, highly expressed in the central nervous system, mediate the psychotropic and metabolic effects of cannabinoids. Selective antagonists like rimonabant (SR141716) enable precise dissection of CB1-dependent pathways, distinguishing them from CB2 and non-cannabinoid signaling (Strategic Insights for Translational Researchers). This specificity is essential in preclinical models investigating appetite regulation and cannabinoid dependence. Compared to non-selective agonists, CB1 antagonists offer targeted modulation with reduced off-target activity, facilitating clearer interpretation of metabolic and behavioral endpoints.

Mechanism of Action of Rimonabant (SR141716)

Rimonabant (SR141716) acts as a competitive antagonist at the central CB1 receptor. By occupying the orthosteric binding site, it prevents endogenous cannabinoids (such as anandamide) and synthetic agonists from activating the receptor. This inhibition reduces downstream signaling through G-protein-coupled cascades, attenuating the effects on appetite, reward, and neuroimmune modulation (Strategic Insights for Translational CB1 Modulation). Its selectivity for CB1 over CB2 is confirmed by binding affinity measurements (Ki = 1.8 nM for CB1; Ki = 514 nM for CB2), minimizing peripheral or immune-related confounds. In vitro, rimonabant induces apoptosis in keratinocytes and alters immune cell populations, further demonstrating its functional impact beyond neuronal circuits (APExBIO product information).

Evidence & Benchmarks

• Rimonabant (SR141716) precipitates quantifiable withdrawal in both male and female rats previously exposed to the synthetic cannabinoid agonist WIN 55,212-2; effective doses are 3 mg/kg in females and 10 mg/kg in males (Sex Differences in Cannabinoid Withdrawal).
• CB1 binding affinity of rimonabant is 1.8 nM, with over 285-fold selectivity versus CB2 (Ki = 514 nM), enabling precise receptor-specific studies (APExBIO product information).
• Rimonabant reduces the consumption of palatable and sweet foods in rodents, with minimal effect on bland food intake, supporting its application in appetite regulation research (Reliable CB1 Antagonist for Appetite Research).
• In vitro exposure to rimonabant decreases keratinocyte viability via apoptosis and alters PBMC immune profiles (APExBIO product information).
• Topical application in mice reduces edema and leukocyte infiltration, demonstrating anti-inflammatory effects in vivo (APExBIO product information).

This article extends prior guidance by focusing on protocol optimization and highlighting sex-specific withdrawal responses not detailed in Strategic Insights for Translational Researchers.

Applications, Limits & Misconceptions

Rimonabant is widely used in research on appetite regulation, obesity, and cannabinoid dependence due to its selectivity and reproducibility. Its validated use in rodent models of withdrawal, feeding behavior, and inflammation provides a robust foundation for translational studies (Applied Workflows in Appetite and Obesity Research). However, certain limitations and frequent misconceptions should be addressed.

Common Pitfalls or Misconceptions

• Not a pan-CB receptor blocker: Rimonabant is highly selective for CB1; it does not significantly inhibit CB2 at typical experimental concentrations (APExBIO product information).
• Water insolubility: Direct dissolution in aqueous buffers is not feasible; use DMSO or ethanol as recommended to achieve effective concentrations.
• Storage instability of solutions: Rimonabant solutions should not be stored long-term, as degradation reduces potency; freshly prepare aliquots and store solids at -20°C.
• Limited behavioral effect scope: In withdrawal models, rimonabant’s effects are dose- and sex-dependent, with variable locomotor changes across conditions (Sex Differences in Cannabinoid Withdrawal).
• Not a therapeutic agent: Rimonabant is not approved for human use due to adverse psychiatric effects; its use is restricted to preclinical research.

Compared to Strategic Insights for Translational CB1 Modulation, this article details specific protocol cautions and addresses sex- and dose-dependencies in withdrawal models.

Workflow Integration & Parameters

• Solvent recommendations: Dissolve rimonabant at ≥23.19 mg/mL in DMSO or ≥57.1 mg/mL in ethanol; avoid water.
• Storage advice: Store solid at -20°C; avoid long-term solution storage. Prepare fresh aliquots for each use (APExBIO product information).
• Withdrawal induction: For rodent withdrawal studies, use 3 mg/kg in females and 10 mg/kg in males, administered intraperitoneally 4 hours after final agonist exposure (Sex Differences in Cannabinoid Withdrawal).
• Feeding studies: Administer rimonabant prior to food presentation to evaluate suppression of palatable food intake (Reliable CB1 Antagonist for Appetite Research).
• Cell assays: For in vitro work, titrate concentrations to match cell line tolerability; apoptosis and immune modulation observed in keratinocytes and PBMCs.

This complements workflows detailed in Applied Workflows in Appetite and Obesity Research by offering current, literature-backed dose and solvent parameters.

Conclusion & Outlook

Rimonabant (SR141716) remains a benchmark selective CB1 antagonist for mechanistic research in appetite regulation, cannabinoid dependence, and inflammation. Its robust selectivity, well-characterized pharmacology, and reproducible performance support advanced experimental designs. Outlook: Recent preclinical evidence underscores the importance of sex-specific and dose-dependent protocols, particularly in withdrawal models, refining translational relevance and protocol accuracy (Sex Differences in Cannabinoid Withdrawal). APExBIO continues to supply validated reagents (SKU B1429) with up-to-date usage recommendations for reproducible endocannabinoid system research.